Iveric Bio announces FDA approval for IZERVAY™️️
Congratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details
Modality Solutions new white paper details how simulated transport is a valuable technique for determining the physical stability of drug product protein solutions, including vaccines, monoclonal antibodies, antibody-drug conjugates (ADCs), and gene therapies. Large molecule drug products may be susceptible to degradation when exposed to common transport hazards. Simulation testing exposes the product to the concurrent combination of these hazards at worst-case edges of your operating space in the global supply chain. Unlike ASTM-based testing, the hazards are applied with realistic durations and intensities that reflect the supply chain’s risks.
The white paper explains:
“An understanding of these methodologies is vital to ensure the simulated transport hazards reflect the actual cold chain for each therapy. “If correctly planned and executed to be included in the BLA, analytical results from samples exposed to concurrent transport simulation are considered industry best practice.”
— Modality Solutions President, Gary Hutchinson.
Click here to view the Simulated Transport Methodologies White Paper press release.
Congratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read DetailsCongratulations to Incyte on their FDA approval for Zynyz™, a treatment for adults with metastatic...
read DetailsCongratulations to Amicus Therapeutics for their European Commission approval for Pombiliti™ in patients with Late-Onset...
read Details